About Us

Nekonal Oncology is an early stage biotechnology company focused on the development of first-in-class antibodies against a novel T cell based target. These treatments could be used as a monotherapy or combination therapy for both solid and hematological malignancies. Currently, the company is characterizing its candidate antibodies and is aiming to select leads for IND enabling work.

Portage shareholders own 25% of Nekonal Oncology. Portage also serves as Chief Executive Officer, Head of Research, provides project management and financial support and holds the Chairman and executive member seats on the Board of Directors.

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Nekonal

ASSET
A
B
INDICATION
Heme Tumor
Solid Tumor
STAGE
IND-Enabling
IND-Enabling

Program

The Company is evaluating novel antibody targets, which are upstream from CTLA4. The antibodies have the potential for dual targeting of the tumor cell directly, as well as the suppressive tumor microenvironment in certain tumor types. Nekonal Oncology has filed for patents globally and has demonstrated in vitro proof of concept for both antibodies. The Company is currently progressing towards in vivo validation.

Leadership

Dr. Walters has over 20 years of leadership and expertise in oncology/immunology …

Nalân Utku, MD is currently Managing Director of Research & …

Non-Executive Director

John Edwards has 30 years of experience in discovery, development …

Head of Research

Robert has 24 years of experience in the pharmaceutical industry and is the …